Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q1 2026

Biovie Q1 2026 Results: Net Loss of $5.61M, Loss Widens

BioVie Inc. reported a net loss of $5.6 million for the quarter ended September 30, 2026, compared to a $5.1 million loss in the prior year period. The company remains in the clinical stage with no revenue, focusing its spending on research and development for neurodegenerative and liver disease therapies.

Q1 2026 at a glance · $ million
MetricQ1 2026Q1 2025
Net income-5.6-5.1
EPS (diluted, $ a share)$-0.68$-0.98

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: BIVI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Biovie Inc.: key numbers

Share price
$0.9953Close, Nov 17
Market cap
$10.7M
Shares outstanding
10.72MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Biovie Inc.

All →
5:03 PM ET 8-K
Shareholder Meeting

Biovie Shareholder Meeting

BioVie Inc. held its 2026 Annual Meeting of Stockholders where shareholders elected six directors to the board and ratified EisnerAmper LLP as the independent auditor for fiscal 2027. Shareholders also approved an amendment to the 2019 Omnibus Equity Incentive Plan, significantly increasing the share pool from 399,509 to 3,100,000 shares.

5:11 PM ET 8-K
Capital Raise

Biovie Capital Raise of $4.74M

BioVie Inc. entered into a securities purchase agreement with an institutional investor for a $4.74 million registered direct offering and concurrent private placement. The company issued 960,000 shares and 2,002,500 pre-funded warrants at $1.60 per share/equivalent, along with 2,962,500 common warrants. Proceeds are intended for working capital and general corporate purposes.

Value
$4.74M
6:01 AM ET 8-K
Other 8-K Filing

Biovie Other 8-K Filing

BioVie Inc. entered into a sales agreement with A.G.P./Alliance Global Partners to establish an at-the-market (ATM) offering program. Under the agreement, the company may issue and sell shares of its Class A common stock having an aggregate offering price of up to approximately $6.46 million from time to time. The company has no obligation to sell any shares and intends to use any potential proceeds for general corporate purposes.

Counterparty
A.G.P./Alliance Global Partners

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.